Skip Navigation

Coronavirus (COVID-19) information for Dana-Farber patients & families Learn more

Harold J. Burstein, MD, PhD


Medical Oncology

Make an Appointment
Watch Video

Physician

  • Institute Physician
  • Professor of Medicine, Harvard Medical School

Centers/Programs

Diseases Treated

Contact Information

  • Appointments617-632-2175 (new)
    617-632-3800 (follow-up)
  • Office Phone Number617-632-3800
  • Fax617-632-1930

Bio

Dr. Burstein graduated from Harvard College before earning his MD at Harvard Medical School. He also received a PhD in cellular immunology and a master's degree in the history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital before his oncology fellowship at DFCI. In 1999, he joined the staff of DFCI and Brigham and Women's Hospital, where he is a clinician and clinical investigator in the Breast Oncology Center.

Board Certification:

  • Internal Medicine, 1997
  • Medical Oncology, 2000

Fellowship:

  • Dana-Farber Cancer Institute, Hematology/Oncology

Residency:

  • Massachusetts General Hospital, Internal Medicine

Medical School:

  • Harvard Medical School

Recent Awards:

  • George P. Canellos Award for Excellence in Clinical Investigation and Patient Care 2001
  • Fellow of the American Society of Clinical Oncology, 2012
  • Dana-Farber Cancer Institute Clinical Mentor Award, 2014

Research

Clinical Investigation of Breast Cancer

In the Breast Oncology Center, our clinical trials help define new treatment options for women with early-stage and advanced breast cancer. These trials use the scientific and laboratory resources at the Dana-Farber/Harvard Cancer Center to translate clinical observations into well-described biological phenomena. Some of our recent studies are described below.We have conducted several NCI-supported phase II trials of angiogenesis inhibitors in advanced breast cancer. These studies analyzed clinical outcomes for treatment with standard or low-dose "metronomic" chemotherapy (also thought to have anti-angiogenic potential) in combination with bevacizumab, an anti-vascular endothelial growth factor (VEGF) antibody. The primary endpoints of these studies are to characterize the response rate and safety profile of treatments. Correlative studies are analyzing baseline and dynamic measures of angiogenesis as predictors of tumor response, including measurement of circulating endothelial cells. Based on encouraging preliminary findings for these trials, we developed a trial of bevacizumab and metronomic chemotherapy that is now open to patients with early-stage breast cancer. This study will also use proteomics to gauge the extent of anti-angiogenic activity.In addition, we are evaluating other novel agents in clinical trials, including various anti-angiogenesis drugs and new formulations of chemotherapy and hormonal therapy.With colleagues in the health services research division at Dana-Farber, we are also exploring optimal use of adjuvant endocrine therapy for breast cancer. In these research efforts, we use computer modeling to help define which treatment strategies (e.g., tamoxifen, an aromatase inhibitor, or sequential treatment with one and then the other) would best prevent cancer recurrence. Such outcomes analyses can help inform clinical decision when direct data are not available to guide recommendations.

Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 Jun 02; JCO2003398.
View in: PubMed

Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 May 19.
View in: PubMed

NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493.
View in: PubMed

Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectr. 2021 Jun; 5(3):pkab025.
View in: PubMed

Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 Apr 06; 113(4):443-452.
View in: PubMed

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply. N Engl J Med. 2021 03 25; 384(12):1176-1177.
View in: PubMed

The global landscape of treatment standards for breast cancer. J Natl Cancer Inst. 2021 Jan 27.
View in: PubMed

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222.
View in: PubMed

Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations. JAMA. 2021 01 05; 325(1):36-38.
View in: PubMed

Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med. 2020 12 24; 383(26):2557-2570.
View in: PubMed

A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2021 Jan; 185(1):135-144.
View in: PubMed

Multidisciplinary considerations in the treatment of triple-negative breast cancer. CA Cancer J Clin. 2020 11; 70(6):432-442.
View in: PubMed

Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020 Jun; 181(3):487-497.
View in: PubMed

Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
View in: PubMed

Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.
View in: PubMed

Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478.
View in: PubMed

The legacy of Professor Aron Goldhirsch. Ann Oncol. 2020 06; 31(6):671-673.
View in: PubMed

Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020 May; 181(1):43-51.
View in: PubMed

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 Oct; 30(10):1541-1557.
View in: PubMed

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 Sep; 30(9):1514-1520.
View in: PubMed

Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.
View in: PubMed

Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol. 2019 Jul; 30(7):1181.
View in: PubMed

Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. Breast. 2019 Nov; 48 Suppl 1:S89-S91.
View in: PubMed

Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 10 01; 30(10):1541-1557.
View in: PubMed

A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.
View in: PubMed

Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
View in: PubMed

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2019 07 01; 30(7):1181.
View in: PubMed

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2019 06 01; 30(6):1019.
View in: PubMed

Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e1-e7.
View in: PubMed

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.
View in: PubMed

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
View in: PubMed

NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126.
View in: PubMed

A Breath-Taking Diagnosis. N Engl J Med. 2019 01 03; 380(1):81-87.
View in: PubMed

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Oncol Pract. 2019 Feb; 15(2):106-107.
View in: PubMed

Duration of adjuvant trastuzumab: might less be more? Ann Oncol. 2018 12 01; 29(12):2273-2274.
View in: PubMed

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 02 10; 37(5):423-438.
View in: PubMed

Information Transparency in the Drug Approval Process. JAMA Oncol. 2018 11 01; 4(11):1621-1622.
View in: PubMed

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01; 29(10):2153.
View in: PubMed

Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. J Am Geriatr Soc. 2019 05; 67(5):920-927.
View in: PubMed

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
View in: PubMed

How Old is Too Old? Breast Cancer Treatment in Octogenarians. Ann Surg Oncol. 2018 06; 25(6):1458-1460.
View in: PubMed

Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar; 16(3):310-320.
View in: PubMed

Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044.
View in: PubMed

Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Ann Oncol. 2018 01 01; 29(1):281-282.
View in: PubMed

Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 01; 19(1):127-138.
View in: PubMed

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 08 01; 28(8):1700-1712.
View in: PubMed

Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.
View in: PubMed

Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 Sep 01; 35(25):2866-2870.
View in: PubMed

NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 04; 15(4):433-451.
View in: PubMed

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
View in: PubMed

Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study. Psychooncology. 2017 08; 26(8):1087-1092.
View in: PubMed

Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? JAMA. 2017 01 03; 317(1):30-32.
View in: PubMed

Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1399-1400.
View in: PubMed

Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? Eur J Surg Oncol. 2016 Dec; 42(12):1780-1786.
View in: PubMed

Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304.
View in: PubMed

Chemotherapy for Triple-Negative Breast Cancer: Is More Better? J Clin Oncol. 2016 10 01; 34(28):3369-71.
View in: PubMed

Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
View in: PubMed

Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. J Oncol Pract. 2016 Jun; 12(6):583-7.
View in: PubMed

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 09 01; 34(25):3069-103.
View in: PubMed

Update in Hematology and Oncology: Evidence Published in 2015. Ann Intern Med. 2016 May 03; 164(9):W32-6.
View in: PubMed

Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10.
View in: PubMed

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. J Oncol Pract. 2016 Apr; 12(4):390-3.
View in: PubMed

Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar; 14(3):324-54.
View in: PubMed

Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016 05 10; 34(14):1689-701.
View in: PubMed

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.
View in: PubMed

NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec; 13(12):1475-85.
View in: PubMed

With better adjuvant therapy, does breast cancer stage still matter? BMJ. 2015 Oct 06; 351:h5273.
View in: PubMed

Adjuvant endocrine therapy for postmenopausal women: Type and duration. Breast. 2015 Nov; 24 Suppl 2:S126-8.
View in: PubMed

Postmenopausal breast cancer: a best endocrine strategy? Lancet. 2015 Oct 03; 386(10001):1317-1319.
View in: PubMed

Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy. N Engl J Med. 2015 Jul 23; 373(4):379-81.
View in: PubMed

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58.
View in: PubMed

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
View in: PubMed

Choosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments? J Oncol Pract. 2015 Jul; 11(4):322-4.
View in: PubMed

Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):448-75.
View in: PubMed

Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
View in: PubMed

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
View in: PubMed

Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.
View in: PubMed

Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66.
View in: PubMed

Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30.
View in: PubMed

Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA1.
View in: PubMed

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7.
View in: PubMed

Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
View in: PubMed

Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014 Jul 01; 32(19):1979-86.
View in: PubMed

Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
View in: PubMed

Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69.
View in: PubMed

Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90.
View in: PubMed

Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014 May 01; 32(13):1365-83.
View in: PubMed

Neoadjuvant pertuzumab: the exception that proves the rule? Oncology (Williston Park). 2014 Mar; 28(3):197-9.
View in: PubMed

Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy. Am Soc Clin Oncol Educ Book. 2014; e1-3.
View in: PubMed

Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80.
View in: PubMed

Trastuzumab: qui bono? J Natl Cancer Inst. 2013 Dec 04; 105(23):1772-5.
View in: PubMed

Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7.
View in: PubMed

Patients with triple negative breast cancer: is there an optimal adjuvant treatment? Breast. 2013 Aug; 22 Suppl 2:S147-8.
View in: PubMed

Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.
View in: PubMed

Lucky to be an oncologist. J Natl Compr Canc Netw. 2013 Aug; 11(8):909-10.
View in: PubMed

Expert opinion vs guideline based care: the St. Gallen Case study. Breast. 2013 Aug; 22 Suppl 2:S1-2.
View in: PubMed

Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Jul; 11(7):753-60; quiz 761.
View in: PubMed

Breast cancer treatment in the era of individualized care. Hematol Oncol Clin North Am. 2013 Aug; 27(4):xiii-xv.
View in: PubMed

Lou Gehrig, Angelina Jolie, and cancer genetics. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):631-2.
View in: PubMed

A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
View in: PubMed

Off-label use of oncology drugs: too much, too little, or just right? J Natl Compr Canc Netw. 2013 May 01; 11(5):505-6.
View in: PubMed

Keeping cancer patients out of the hospital at the end of life. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):229-30.
View in: PubMed

High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
View in: PubMed

Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31.
View in: PubMed

Caring for breast cancer survivors. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):1-2.
View in: PubMed

Implementation of team training in outpatient breast oncology. J Clin Oncol. 2012 Dec; 30(34_suppl):83.
View in: PubMed

Measuring hope: patient expectations of chemotherapy for advanced cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1459-60.
View in: PubMed

A "shot heard 'round the world" on cancer drug costs? J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1315-6.
View in: PubMed

Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer? J Clin Oncol. 2012 Nov 10; 30(32):3916-20.
View in: PubMed

Assuring access to academic cancer centers. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1177-8.
View in: PubMed

Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78.
View in: PubMed

Pathway-based oncology care: time for more transparency. J Natl Compr Canc Netw. 2012 Sep; 10(9):1043-4.
View in: PubMed

Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51.
View in: PubMed

Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J. 2012 Jul-Aug; 18(4):303-11.
View in: PubMed

Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):797-8.
View in: PubMed

Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):821-9.
View in: PubMed

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92.
View in: PubMed

The top five in oncology: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 01; 10(6):681-2.
View in: PubMed

Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat. 2012 Jun; 133(2):677-83.
View in: PubMed

Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82.
View in: PubMed

If the choices are all the same, why not prefer the less-expensive option? J Natl Compr Canc Netw. 2012 Apr; 10(4):425-6.
View in: PubMed

Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise? Nat Rev Clin Oncol. 2012 Mar 13; 9(4):191-2.
View in: PubMed

Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.
View in: PubMed

Pre-judging data: benchmarking clinical significance before study results are known. J Natl Compr Canc Netw. 2012 Mar; 10(3):289-90.
View in: PubMed

Disclosing pharma payments to oncologists: what will we learn? J Natl Compr Canc Netw. 2012 Feb; 10(2):133-4.
View in: PubMed

Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. J Clin Oncol. 2012 Mar 01; 30(7):684-6.
View in: PubMed

Update of the oxford overview: new insight and perspectives in the era of personalized medicine. Am Soc Clin Oncol Educ Book. 2012; 71-9.
View in: PubMed

JNCCN reaches 10. J Natl Compr Canc Netw. 2012 Jan; 10(1):3.
View in: PubMed

Avastin for breast cancer, 2005-2011: requiescat in pacem? J Natl Compr Canc Netw. 2011 Dec; 9(12):1321-3.
View in: PubMed

The continuity of care checklist: a critical frontier in patient safety. J Natl Compr Canc Netw. 2011 Nov; 9(11):1217-8.
View in: PubMed

Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7.
View in: PubMed

Patients with anti-HER2 responsive disease: definition and adjuvant therapies. Breast. 2011 Oct; 20 Suppl 3:S132-4.
View in: PubMed

Have we been down this road before? J Natl Compr Canc Netw. 2011 Sep 01; 9(9):953.
View in: PubMed

Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9.
View in: PubMed

American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30.
View in: PubMed

The fifth "C" is cost: highlights from ASCO 2011. J Natl Compr Canc Netw. 2011 Jul 01; 9(7):691.
View in: PubMed

Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer. 2012 Feb 01; 118(3):603-11.
View in: PubMed

Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):459-65.
View in: PubMed

CMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11.
View in: PubMed

Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S1-2.
View in: PubMed

Novel agents and future directions for refractory breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S17-24.
View in: PubMed

Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074.
View in: PubMed

Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2011 May; 9(5 Suppl 11):1-16.
View in: PubMed

Texting the doctor. J Natl Compr Canc Netw. 2011 May; 9(5):459.
View in: PubMed

Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.
View in: PubMed

Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011 Jul; 58(1):85-92.
View in: PubMed

Mind the gap. J Natl Compr Canc Netw. 2011 Apr; 9(4):343.
View in: PubMed

Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011 Dec; 22(12):2582-2590.
View in: PubMed

Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol. 2011 Apr 01; 29(10):1232-5.
View in: PubMed

EMBRACE, eribulin, and new realities of advanced breast cancer. Lancet. 2011 Mar 12; 377(9769):878-80.
View in: PubMed

Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
View in: PubMed

Take your medicine. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 3:S1.
View in: PubMed

Invasive breast cancer. J Natl Compr Canc Netw. 2011 Feb; 9(2):136-222.
View in: PubMed

Take Your Medicine J Natl Compr Canc Netw. 2011 Feb 01; 9(9 Suppl 3):S1.
View in: PubMed

Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
View in: PubMed

Beaten at the Alamo by the Europeans. J Natl Compr Canc Netw. 2011 Jan; 9(1):1.
View in: PubMed

Board recertification. J Natl Compr Canc Netw. 2010 Oct; 8(10):1111.
View in: PubMed

Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207.
View in: PubMed

Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104.
View in: PubMed

Addressing oncology pharmacy & policy. J Natl Compr Canc Netw. 2010 Sep; 8 Suppl 7:S1.
View in: PubMed

American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010 Sep; 6(5):243-6.
View in: PubMed

Avastin, ODAC, and the FDA: are we drafting the right players? J Natl Compr Canc Netw. 2010 Aug; 8(8):833-4.
View in: PubMed

American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96.
View in: PubMed

Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010 Jul; 19(3):639-47.
View in: PubMed

SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376.
View in: PubMed

Re-engineering the cooperative groups. J Natl Compr Canc Netw. 2010 May; 8(5):505.
View in: PubMed

Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010 Mar 10; 28(8):1301-7.
View in: PubMed

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1124-30.
View in: PubMed

Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3.
View in: PubMed

Screening contretemps: the real issue in the mammogram guideline debate. J Natl Compr Canc Netw. 2009 Nov; 7(10):1039-40.
View in: PubMed

Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. Breast. 2009 Oct; 18 Suppl 3:S135-6.
View in: PubMed

What is a patient navigator, and should we have them in major cancer centers? J Natl Compr Canc Netw. 2009 Oct; 7(9):905.
View in: PubMed

NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3.
View in: PubMed

Colon cancer: the new breast cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):773.
View in: PubMed

NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 5:S1-S26; quiz S27-8.
View in: PubMed

Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N Engl J Med. 2009 Aug 13; 361(7):699-707.
View in: PubMed

Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol. 2009 Sep 01; 27(25):4182-7.
View in: PubMed

Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009 Nov; 20(11):1771-85.
View in: PubMed

Quality measures, clinical practice, NCCN, and McAllen, Texas. J Natl Compr Canc Netw. 2009 Jul; 7(7):695.
View in: PubMed

Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. J Clin Oncol. 2009 May 20; 27(15_suppl):572.
View in: PubMed

Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
View in: PubMed

Do clinical trials belong in clinical guidelines? J Natl Compr Canc Netw. 2009 May; 7(5):489.
View in: PubMed

By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram? Harv Health Lett. 2009 May; 34(7):2.
View in: PubMed

SPIKES for difficult conversations with cancer patients. J Natl Compr Canc Netw. 2009 Apr; 7(4):341.
View in: PubMed

Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23.
View in: PubMed

Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.
View in: PubMed

Personalized medicine and breast cancer care. J Natl Compr Canc Netw. 2009 Feb; 7(2):109.
View in: PubMed

Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009 Jun; 20(6):1026-31.
View in: PubMed

Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009 Jan-Mar; 24(1):1-10.
View in: PubMed

AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. Gene Ther. 2009 Mar; 16(3):426-36.
View in: PubMed

Updates in anti-HER2 combination therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):873-4.
View in: PubMed

VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
View in: PubMed

Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000.
View in: PubMed

Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity. Oncology (Williston Park). 2008 Nov 15; 22(12):1416, 1424.
View in: PubMed

Conflict of interest and oncology guidelines. J Natl Compr Canc Netw. 2008 Nov; 6(10):955.
View in: PubMed

Oncology teamwork. J Natl Compr Canc Netw. 2008 Sep; 6(8):715.
View in: PubMed

NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2.
View in: PubMed

Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6.
View in: PubMed

Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12.
View in: PubMed

A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):1015.
View in: PubMed

A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):519.
View in: PubMed

Cancer-related direct-to-consumer advertising: awareness, perceived impact, and associated patient and provider behavior. J Clin Oncol. 2008 May 20; 26(15_suppl):6631.
View in: PubMed

Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 07; 100(9):642-8.
View in: PubMed

Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
View in: PubMed

Preoperative therapy as a model for translational research in breast cancer. Cancer Invest. 2008 Apr-May; 26(3):217-21.
View in: PubMed

Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9.
View in: PubMed

Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
View in: PubMed

Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1198-200.
View in: PubMed

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008 Jun; 19(6):1068-74.
View in: PubMed

Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9.
View in: PubMed

Molecular origins of cancer. N Engl J Med. 2008 Jan 31; 358(5):527.
View in: PubMed

NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7.
View in: PubMed

Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 01; 25(25):3797-9.
View in: PubMed

Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 01; 110(5):965-72.
View in: PubMed

Cognitive side-effects of adjuvant treatments. Breast. 2007 Dec; 16 Suppl 2:S166-8.
View in: PubMed

NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May; 5 Suppl 1:S1-22; quiz S23-2.
View in: PubMed

Biological basis of breast cancer: an introduction. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S1-3.
View in: PubMed

Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):257-72.
View in: PubMed

Anemia in cancer: update on studies of erythropoiesis-stimulating agents. J Support Oncol. 2007 Apr; 5(4 Suppl 2):5-26.
View in: PubMed

Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007 Jun; 16(3):223-34.
View in: PubMed

Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
View in: PubMed

Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312.
View in: PubMed

Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw. 2007 Mar; 5(3):314-23.
View in: PubMed

Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
View in: PubMed

Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007; 9(5):110.
View in: PubMed

Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Oncology (Williston Park). 2006 Dec; 20(14 Suppl 9):13-5.
View in: PubMed

Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1.
View in: PubMed

The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2.
View in: PubMed

Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4.
View in: PubMed

Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007 Feb; 18(2):215-25.
View in: PubMed

HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4.
View in: PubMed

Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):578.
View in: PubMed

Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10564.
View in: PubMed

Use of experimental therapy outside of clinical trials among U.S. oncologists. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6047.
View in: PubMed

Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):650.
View in: PubMed

The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82.
View in: PubMed

Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61.
View in: PubMed

NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.
View in: PubMed

Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8.
View in: PubMed

Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
View in: PubMed

Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
View in: PubMed

The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20; 353(16):1652-4.
View in: PubMed

American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20.
View in: PubMed

Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7.
View in: PubMed

Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA. Expert Rev Anticancer Ther. 2005 Aug; 5(4):581-3.
View in: PubMed

Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 01; 23(22):5178-87.
View in: PubMed

Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol. 2005 Jun; 23(16_suppl):563.
View in: PubMed

Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):529.
View in: PubMed

Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89.
View in: PubMed

HER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 01; 23(16):3656-9.
View in: PubMed

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
View in: PubMed

American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004 Sep 01; 22(17):3631-8.
View in: PubMed

Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):547.
View in: PubMed

Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. J Clin Oncol. 2004 Jul 15; 22(14_suppl):544.
View in: PubMed

Ductal carcinoma in situ of the breast. N Engl J Med. 2004 Apr 01; 350(14):1430-41.
View in: PubMed

Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2003 Dec; 4(5):329-37; discussion 338-9.
View in: PubMed

Follow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25.
View in: PubMed

Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer. N Engl J Med. 2003 Nov 06; 349(19):1857-9.
View in: PubMed

Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
View in: PubMed

Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
View in: PubMed

Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7.
View in: PubMed

American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.
View in: PubMed

Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51.
View in: PubMed

Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2.
View in: PubMed

Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
View in: PubMed

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
View in: PubMed

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43.
View in: PubMed

Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400.
View in: PubMed

HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol. 2002 Apr; 3(2):163-74.
View in: PubMed

Treatment of breast cancer during pregnancy. Expert Opin Pharmacother. 2002 Apr; 3(4):423-8.
View in: PubMed

New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
View in: PubMed

Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in: PubMed

Unusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers. J Clin Oncol. 2001 May 01; 19(9):2571-3.
View in: PubMed

Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42.
View in: PubMed

New combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7.
View in: PubMed

Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94.
View in: PubMed

Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol. 2000 Jul; 18(13):2501-4.
View in: PubMed

Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
View in: PubMed

Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol. 2000 Feb; 18(3):693-4.
View in: PubMed

Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
View in: PubMed

Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999 Jun 03; 340(22):1733-9.
View in: PubMed

Hypertrophic osteoarthropathy. J Clin Oncol. 1997 Jul; 15(7):2759-60.
View in: PubMed

Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Adv Exp Med Biol. 1995; 362:399-406.
View in: PubMed

Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J Biol Chem. 1994 Apr 15; 269(15):11170-7.
View in: PubMed

Determinants of helper T cell-dependent antibody production. Semin Immunol. 1993 Dec; 5(6):441-7.
View in: PubMed

In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J Exp Med. 1993 Feb 01; 177(2):457-63.
View in: PubMed

Proteolysis in the maturation of avian retroviruses does not require calcium. Virology. 1992 Aug; 189(2):771-4.
View in: PubMed

Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. J Immunol. 1992 Jun 15; 148(12):3687-91.
View in: PubMed

Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem. 1992 May 15; 267(14):9481-90.
View in: PubMed

Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem. 1992 May 15; 267(14):9491-8.
View in: PubMed

Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J Virol. 1992 Mar; 66(3):1781-5.
View in: PubMed

Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol. 1991 Nov; 65(11):6165-72.
View in: PubMed

Humoral immune functions in IL-4 transgenic mice. J Immunol. 1991 Nov 01; 147(9):2950-6.
View in: PubMed

Activation and functions of CD4+ T-cell subsets. Immunol Rev. 1991 Oct; 123:5-22.
View in: PubMed

T-cell-mediated activation of B cells. Curr Opin Immunol. 1991 Jun; 3(3):345-9.
View in: PubMed

Functional phospholipid/sphingomyelin ratio: an easy to interpret indicator of fetal lung maturity. Ann Clin Lab Sci. 1986 Sep-Oct; 16(5):407-11.
View in: PubMed

Degree of unsaturation of the fatty acid chains of phospholipids influences the fluorescence polarization: implications for evaluating fetal lung maturity. Clin Chem. 1986 Mar; 32(3):425-8.
View in: PubMed

MAMMARY PAGET'S DISEASE. Skin (Los Angeles). 1964 Jul; 3:206-11.
View in: PubMed

Location

Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215
Get Directions

Dana-Farber Cancer Institute - Chestnut Hill
300 Boylston Street
Newton, MA 02459
Get Directions

Ratings

Top